EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitSystematische ÜbersichtMetaanalyse

Vedolizumab Trough Concentrations and Clinical and Endoscopic Outcomes in Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis

Mostafa A Soliman, Alessandra Saraga, Ajay Gade, Sadra Habibi Moini, Benjamin Mecsas-Faxon, Loren G Rabinowitz, Isabella Midura, Tamara Knezevic Ivanovski, Xavier Roblin, Laurent Peyrin-Biroulet, Adam S Cheifetz, Konstantinos Papamichael

Clinical Gastroenterology and Hepatology · 2026-09

DOI: 10.1016/j.cgh.2026.09.009 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Clinical Gastroenterology and Hepatology, 2026-09. Verfasst von Mostafa A Soliman und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Beth-Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts. Electronic address: msolima5@bidmc.harva…. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 55 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND & AIMS: The role of therapeutic drug monitoring in optimizing vedolizumab (VDZ) therapy for Crohn's disease (CD) and ulcerative colitis (UC) remains unclear. Prior evidence was limited by small sample size and heterogeneous endpoints. We synthesized the available evidence on the association of VDZ trough concentrations with clinical (CR) and endoscopic remission (ER). METHODS: Following Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 2020 guidelines, we searched the literature from inception to April 2026 for studies reporting VDZ trough concentrations stratified by remission status in CD and UC. Outcomes were CR and ER. Pooled mean differences (MDs) were estimated using random-effects models with restricted maximum likelihood estimation; heterogeneity was quantified using the I2 statistic. RESULTS: Twenty-three studies (6753 patients) met inclusion criteria; 18 contributed to quantitative synthesis. Higher VDZ trough concentrations were strongly associated with ER in UC (MD, 4.86 μg/mL; 95% confidence interval, 2.75-6.98; P < .0001; I2 = 0.0%). Higher concentrations were also associated with CR in UC (MD, 3.18 μg/mL; P = .025) and CD (MD, 3.08 μg/mL; P < .0001), although these clinical remission estimates were statistically heterogeneous; no association was observed for ER in CD (MD, 1.40 μg/mL; P = .453). Pooled remission-associated concentrations were presented descriptively and supported maintenance targets of ≥13 to 15 μg/mL in UC and ≥10 to 12 μg/mL in CD. CONCLUSIONS: Higher VDZ trough concentrations were associated with remission, most robustly for ER in UC. As these associations are largely cross-sectional, they may reflect reverse causation rather than a dose-response relationship. Prospective interventional trials are required before proactive therapeutic drug monitoring can be recommended.

Schlagwörter

Stichwörter der Autor:innen

Crohn’s DiseaseRemissionTherapeutic Drug MonitoringTrough ConcentrationUlcerative ColitisVedolizumab

Autor:innen und Institutionen

  • Department of Medicine, Beth-Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts. Electronic address: msolima5@bidmc.harvard.edu.
  • Department of Medicine, Beth-Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts.
  • Clinic for Gastroenterology and Hepatology, University Hospital Medical Center "Zvezdara", Belgrade, Serbia; Faculty of Medicine, University of Belgrade, Belgrade, Serbia.
  • IBD Unit, Department of Gastroenterology and Hepatology, University Hospital of Saint-Étienne (CHU Saint-Étienne), Saint-Étienne, France.
  • Northwestern Medicine, Digestive Health Institute, Chicago, Illinois.

Zitieren

APA

Soliman, M. A., Saraga, A., Gade, A., Moini, S. H., Mecsas-Faxon, B., Rabinowitz, L. G., Midura, I., Ivanovski, T. K., Roblin, X., Peyrin-Biroulet, L., Cheifetz, A. S., & Papamichael, K. (2026). Vedolizumab Trough Concentrations and Clinical and Endoscopic Outcomes in Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis. Clinical Gastroenterology and Hepatology. https://doi.org/10.1016/j.cgh.2026.09.009

Vancouver

Soliman MA, Saraga A, Gade A, Moini SH, Mecsas-Faxon B, Rabinowitz LG, et al. Vedolizumab Trough Concentrations and Clinical and Endoscopic Outcomes in Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis. Clinical Gastroenterology and Hepatology. 2026. doi:10.1016/j.cgh.2026.09.009

BibTeX
@article{Soliman2026,
  author = {Soliman, Mostafa A and Saraga, Alessandra and Gade, Ajay and Moini, Sadra Habibi and Mecsas-Faxon, Benjamin and Rabinowitz, Loren G and Midura, Isabella and Ivanovski, Tamara Knezevic and Roblin, Xavier and Peyrin-Biroulet, Laurent and Cheifetz, Adam S and Papamichael, Konstantinos},
  title = {Vedolizumab Trough Concentrations and Clinical and Endoscopic Outcomes in Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis},
  journal = {Clinical Gastroenterology and Hepatology},
  year = {2026},
  doi = {10.1016/j.cgh.2026.09.009}
}
Kostenlos starten →